Antifungal Prophylaxis in the Treatment Combination of Hypomethylating Agents and Venetoclax for AML: A Survey Study of the Turkish Society of Hematology Subcommittee on Infections and Supportive Therapies in Hematology.
作者信息
Alp Kırkızlar Tuğcan, Özkocaman Vildan
机构信息
Trakya University Faculty of Medicine, Department of Hematology, Edirne, Türkiye
Bursa Uludağ University Faculty of Medicine, Department of Hematology, Bursa, Türkiye
出版信息
Turk J Haematol. 2025 Feb 28;42(1):69-71. doi: 10.4274/tjh.galenos.2024.2024.0436. Epub 2024 Dec 25.
Abstract
摘要
相似文献
1
Antifungal Prophylaxis in the Treatment Combination of Hypomethylating Agents and Venetoclax for AML: A Survey Study of the Turkish Society of Hematology Subcommittee on Infections and Supportive Therapies in Hematology.抗真菌预防在急性髓系白血病低甲基化药物与维奈克拉联合治疗中的应用：土耳其血液学会血液学感染与支持治疗小组委员会的一项调查研究
Turk J Haematol. 2025 Feb 28;42(1):69-71. doi: 10.4274/tjh.galenos.2024.2024.0436. Epub 2024 Dec 25.
2
Combining azole antifungals with venetoclax plus azacitidine in patients with newly diagnosed acute myeloid leukemia.联合唑类抗真菌药物与维奈托克联合阿扎胞苷治疗新诊断的急性髓系白血病患者。
Hematology. 2024 Dec;29(1):2433172. doi: 10.1080/16078454.2024.2433172. Epub 2024 Nov 25.
3
Antifungal prophylaxis in adult patients with acute myeloid leukaemia treated with novel targeted therapies: a systematic review and expert consensus recommendation from the European Hematology Association.接受新型靶向治疗的成年急性髓系白血病患者的抗真菌预防：欧洲血液学协会的系统评价和专家共识推荐
Lancet Haematol. 2022 May;9(5):e361-e373. doi: 10.1016/S2352-3026(22)00073-4.
4
Should patients with acute myeloid leukemia treated with venetoclax-based regimens receive antifungal prophylaxis?采用维奈托克为基础方案治疗的急性髓系白血病患者是否需要接受抗真菌预防治疗？
Leuk Res. 2023 Aug;131:107341. doi: 10.1016/j.leukres.2023.107341. Epub 2023 Jun 14.
5
Safety and infection risk factors in elderly acute myeloid leukemia patients undergoing induction therapy with venetoclax combined with hypomethylating agents.接受维奈克拉联合去甲基化药物诱导治疗的老年急性髓系白血病患者的安全性和感染风险因素
Am J Cancer Res. 2024 Dec 15;14(12):5897-5908. doi: 10.62347/VZZV6163. eCollection 2024.
6
Challenges and considerations for antifungal prophylaxis in children with acute myeloid leukemia.急性髓系白血病患儿抗真菌预防的挑战与考量。
Expert Rev Hematol. 2024 Oct;17(10):679-686. doi: 10.1080/17474086.2024.2390639. Epub 2024 Aug 12.
7
Real-life monocentric experience of venetoclax-based regimens for acute myeloid leukemia.基于维奈克拉方案治疗急性髓系白血病的真实单中心经验。
Front Oncol. 2023 Mar 27;13:1149298. doi: 10.3389/fonc.2023.1149298. eCollection 2023.
8
Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax.接受低甲基化剂和维奈托克治疗的新诊断 AML 患者抗真菌预防的结果。
Leuk Lymphoma. 2022 Aug;63(8):1934-1941. doi: 10.1080/10428194.2022.2047964. Epub 2022 Mar 15.
9
Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents. Venetoclax 联合低甲基化药物治疗急性髓系白血病中的侵袭性真菌感染。
Blood Adv. 2019 Dec 10;3(23):4043-4049. doi: 10.1182/bloodadvances.2019000930.
10
Strategies for the prophylaxis of invasive fungal diseases in acute myeloid leukemia patients undergoing Bcl-2 inhibitor venetoclax treatment.
J Infect Chemother. 2025 Feb;31(2):102576. doi: 10.1016/j.jiac.2024.12.005. Epub 2024 Dec 4.
本文引用的文献
1
Fungal infection frequency in newly diagnosed acute myeloid leukaemia patients treated with venetoclax plus azacitidine with or without antifungal prophylaxis.新诊断的急性髓系白血病患者接受维奈托克联合阿扎胞苷治疗时是否进行抗真菌预防与真菌感染频率的关系。
Br J Haematol. 2024 Nov;205(5):1746-1750. doi: 10.1111/bjh.19670. Epub 2024 Jul 23.
2
IFISTRATEGY: Spanish National Survey of Invasive Fungal Infection in Hemato-Oncologic Patients.IFISTRATEGY：西班牙血液肿瘤患者侵袭性真菌感染全国调查
J Fungi (Basel). 2023 May 30;9(6):628. doi: 10.3390/jof9060628.
3
Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies: 2022 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).血液恶性肿瘤患者侵袭性真菌病的一级预防：德国血液学和肿瘤内科学会（DGHO）传染病工作组（AGIHO）的建议 2022 年更新版。
J Antimicrob Chemother. 2023 Aug 2;78(8):1813-1826. doi: 10.1093/jac/dkad143.
4
Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN).急性白血病中靶向药物和生物疗法的感染并发症。欧洲白血病感染会议（ECIL）制定的临床实践指南，该会议由欧洲血液与骨髓移植组（EBMT）、欧洲癌症研究与治疗组织（EORTC）、国际免疫受损宿主协会（ICHS）和欧洲白血病网（ELN）联合举办。
Leukemia. 2022 May;36(5):1215-1226. doi: 10.1038/s41375-022-01556-7. Epub 2022 Apr 2.
5
Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax.接受低甲基化剂和维奈托克治疗的新诊断 AML 患者抗真菌预防的结果。
Leuk Lymphoma. 2022 Aug;63(8):1934-1941. doi: 10.1080/10428194.2022.2047964. Epub 2022 Mar 15.
6
Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent.接受 venetoclax 和低甲基化剂治疗的急性髓系白血病患者感染的特征。
Br J Haematol. 2022 Apr;197(1):63-70. doi: 10.1111/bjh.18051. Epub 2022 Feb 16.
7
Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents. Venetoclax 联合低甲基化药物治疗急性髓系白血病中的侵袭性真菌感染。
Blood Adv. 2019 Dec 10;3(23):4043-4049. doi: 10.1182/bloodadvances.2019000930.
Zotero 插件